Search results
Results from the WOW.Com Content Network
Molecular Therapy is a scientific journal, published by Cell Press, that aims to develop and explore "molecular and cellular therapeutics to correct genetic and acquired diseases". [ 1 ] The founder of the journal and its Editor-in-Chief in the first five years was Inder Verma .
Pages in category "Genetics journals" The following 60 pages are in this category, out of 60 total. ... Molecular Therapy; Mouse News Letter; Mutation Research ...
Targeted Therapy Database (TTD) from the Melanoma Molecular Map Project ; Targeted therapy Fact sheet from the U.S. National Cancer Institute; Molecular Oncology: Receptor-Based Therapy Special issue of Journal of Clinical Oncology (April 10, 2005) dedicated to targeted therapies in cancer treatment
Molecular Cancer is a peer-reviewed open-access scientific journal covering all aspects of cancer research. The journal is published by BioMed Central and was established in 2002. The first editor-in-chief was Chi V. Dang, who is also the scientific director of the Ludwig Institute for Cancer Research. [1]
Cell Press published its first open access journal, Cell Reports, in 2012. [3] In January 2021, all Cell Press journals began offering open access publishing options. [4] As of May 2022, Cell Press publishes 17 open access journals and 40 hybrid journals. In 2021, 50% of all articles published in Cell Press were open access. [5]
He was President of the International Society for Cellular Therapy and President of the American Society of Gene Therapy in 2002–2003. He was appointed Editor in Chief of the journal Molecular Therapy in 2009. [3] Dr. Brenner was appointed Director of the Center for Cell and Gene Therapy. Dr.
Molecular oncology is an interdisciplinary medical specialty at the interface of medicinal chemistry and oncology that refers to the investigation of the chemistry of cancer and tumors at the molecular scale. Also the development and application of molecularly targeted therapies.
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...